KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) Shares Outstanding (Weighted Average): 2011-2024

Historic Shares Outstanding (Weighted Average) for TherapeuticsMD (TXMD) over the last 14 years, with Dec 2024 value amounting to $11.5 million.

  • TherapeuticsMD's Shares Outstanding (Weighted Average) rose 0.36% to $11.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.6 million, marking a year-over-year increase of 0.36%. This contributed to the annual value of $11.5 million for FY2024, which is 9.05% up from last year.
  • As of FY2024, TherapeuticsMD's Shares Outstanding (Weighted Average) stood at $11.5 million, which was up 9.05% from $10.6 million recorded in FY2023.
  • TherapeuticsMD's 5-year Shares Outstanding (Weighted Average) high stood at $11.5 million for FY2024, and its period low was $5.5 million during FY2020.
  • Over the past 3 years, TherapeuticsMD's median Shares Outstanding (Weighted Average) value was $10.6 million (recorded in 2023), while the average stood at $10.5 million.
  • Data for TherapeuticsMD's Shares Outstanding (Weighted Average) shows a peak YoY skyrocketed of 55.76% (in 2021) over the last 5 years.
  • TherapeuticsMD's Shares Outstanding (Weighted Average) (Yearly) stood at $5.5 million in 2020, then soared by 55.76% to $8.5 million in 2021, then rose by 11.40% to $9.5 million in 2022, then rose by 11.71% to $10.6 million in 2023, then grew by 9.05% to $11.5 million in 2024.